Malaysia's dengue surge outpaces vaccine uptake as cost and awareness lag

Malaysia is in the grip of a dengue outbreak that has no clear end in sight. Through mid-August 2026, the country recorded 58,079 cases and 55 deaths—a 56.2 percent jump from the same period the year before. The virus has spread unevenly across the archipelago, with Selangor bearing the heaviest load at 25,090 infections, but the surge has reached into corners of the country that had previously seen relative calm. Perlis, a small northern state, recorded a staggering 207 percent increase. Johor more than doubled its caseload. Even Kuala Lumpur and Putrajaya, the federal territories at the heart of the nation, saw cases climb 106 percent. Only three states—Penang, Melaka, and Kedah—managed to push cases downward.

Yet as the virus spreads, the tool that could slow it sits largely unused. Malaysia has a dengue vaccine. It works. But almost nobody is getting it. The reasons are straightforward and stubborn: it costs too much, people don't know enough about it, and the health system has not made it easy to access. Dr. Shanmuganathan TV Ganeson, president of the Federation of Private Medical Practitioners' Associations, laid out the arithmetic plainly. A full two-dose course runs between 420 and 500 Malaysian ringgit—roughly 132 to 158 Singapore dollars—depending on where you go. General practitioner clinics offer it cheaper than hospital facilities, but they lack the marketing muscle of larger institutions. The vaccine also faces an unlikely competitor: the flu shot. For less than 100 ringgit, Malaysians can protect themselves against influenza, a disease most people understand and fear. The dengue vaccine, by contrast, is expensive, unfamiliar, and abstract. Travelers especially tend to choose the flu jab. It's the rational choice when money is tight.

The cost barrier is real, but it is not the whole story. Zamberi Sekawi, co-chairman of Dengue Prevention Advocacy Malaysia, pushed back against the idea that low uptake reflects vaccine hesitancy or anti-vaccine sentiment. What he sees instead is uncertainty. Malaysians want to know whether the vaccine actually works. They want long-term safety data. They want their doctors to tell them it's worth the money. And they want to understand dengue itself—what it is, who gets it, why it matters. The evidence, Sekawi said, suggests that acceptance rises sharply when people grasp the actual risk and when their physician personally recommends the jab. Right now, neither condition is met. Public education is thin. Many doctors lack confidence in the vaccine or haven't been trained to discuss it with patients. The conversation simply isn't happening.

There are also medical constraints. The vaccine cannot be given to pregnant women, breastfeeding mothers, or people with compromised immune systems. It is approved only for those between four and sixty years old. These limitations narrow the eligible population and add another layer of complexity to the public health message.

The Health Ministry, in a statement issued on August 21, acknowledged the crisis. Cases had begun in the Klang Valley—Selangor, Kuala Lumpur, Putrajaya—but have since spread to multiple other states. The ministry said it has begun intensive prevention efforts: early detection, mosquito control, outbreak management, and personnel mobilization. These measures, it claimed, are starting to show results. But the ministry also made clear that it has no immediate plans to add the dengue vaccine to Malaysia's National Immunisation Programme, the publicly funded schedule that makes vaccines free or nearly free to all citizens. That decision, more than any other, explains why uptake remains low. Until the vaccine is subsidized or free, it will remain a luxury good in a country where many people cannot afford it. The outbreak will continue to spread while the tool to stop it sits on pharmacy shelves, waiting for customers who may never come.